Your AI-Trained Oncology Knowledge Connection!


Video

Dr. Umamaheswar Duvvuri on Impact of Multiple Genetic Mutations in Advanced Thyroid Cancer

Umamaheswar Duvvuri, MD, PhD, Assistant Professor of Otolaryngology (ENT) at the University of Pittsburgh Medical Center, talks about potential genetic signatures for locally advanced, well differentiated thyroid cancers.

Umamaheswar Duvvuri, MD, PhD, assistant professor of Otolaryngology (ENT) at the University of Pittsburgh Medical Center, talks about potential genetic signatures for locally advanced, well-differentiated thyroid cancers.

Through the use of next-generation sequencing, it was determined that advanced thyroid cancers are more likely to have multiple mutations than less advanced disease, explains Duvvuri.

Most commonly these advanced cancers seem to have a combination of a BRAF mutation as well as mutation of the promoter region of telomerase reverse transcriptase (hTERT). This may indicate that these two mutations together can cause more aggressive thyroid cancers to form, says Duvvuri.

<<<

View more from the 2015 International Thyroid Congress

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Jordyn Silverstein, MD
Rachel N. Grisham, MD
Toon Van Gorp, MD, PhD
Paul G. Richardson, MD
Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.
Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer
Dr Jagsi on Factors for RT Omission After Breast-Conserving Surgery in Early Breast Cancer